

# Patrick A Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6536366/publications.pdf>

Version: 2024-02-01

148  
papers

6,128  
citations

125106

35  
h-index

84171

75  
g-index

150  
all docs

150  
docs citations

150  
times ranked

9969  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. <i>Blood Advances</i> , 2023, 7, 575-585.	2.5	52
2	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	0.6	28
3	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 1961-1968.	2.5	47
4	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. <i>Blood Advances</i> , 2022, 6, 600-610.	2.5	32
5	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2022, 40, 932-944.	0.8	93
6	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. <i>Journal of Clinical Oncology</i> , 2022, 40, 956-967.	0.8	42
7	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 73.e1-73.e9.	0.6	20
8	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. <i>European Journal of Cancer</i> , 2022, 164, 1-17.	1.3	24
9	Outstanding outcomes in infants with &lt;i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	1.7	11
10	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	0.8	79
11	Decitabine and vorinostat with <sc>FLAG</sc> chemotherapy in pediatric relapsed/refractory <sc>AML</sc>: Report from the therapeutic advances in childhood leukemia and lymphoma (<sc>TACL</sc>) consortium. <i>American Journal of Hematology</i> , 2022, 97, 613-622.	2.0	19
12	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i> , 2022, 40, 2023-2035.	0.8	36
13	Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in <i>KMT2A</i>-rearranged leukemia. <i>Blood</i> , 2022, 139, 2198-2211.	0.6	37
14	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4251-4255.	2.5	20
15	Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel. <i>Journal of Clinical Oncology</i> , 2022, 40, 10016-10016.	0.8	0
16	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 1067-1078.	1.7	15
17	Intrathecal chemotherapy-associated cerebral vasospasm in children with hematologic malignancies. <i>Pediatric Research</i> , 2021, 89, 858-862.	1.1	5
18	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. <i>Leukemia</i> , 2021, 35, 1279-1290.	3.3	46

#	ARTICLE	IF	CITATIONS
19	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	7.7	16
20	Neonatal Leukemia. <i>Clinics in Perinatology</i> , 2021, 48, 15-33.	0.8	9
21	Bromodomain and extra-terminal inhibitors: A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children: ACCELERATE. <i>European Journal of Cancer</i> , 2021, 146, 115-124.	1.3	10
22	TCR $\beta$ chain-directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	30
23	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 833.	3.8	177
24	Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28946.	0.8	3
25	Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. <i>Nature Biomedical Engineering</i> , 2021, 5, 360-376.	11.6	10
26	Resolving driver events in MLL-r negative high-risk infant ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 10030-10030.	0.8	0
27	Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 611-620.	1.9	4
28	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 2138-2142.	0.6	5
29	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	2.3	96
30	Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia. <i>Blood</i> , 2021, 138, 2203-2203.	0.6	0
31	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2021, 138, 363-363.	0.6	8
32	Acute Leukemia and COVID-19: The Johns Hopkins Experience. <i>Blood</i> , 2021, 138, 4046-4046.	0.6	0
33	Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL. <i>British Journal of Haematology</i> , 2020, 188, e36-e39.	1.2	6
34	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. <i>Cancer Research</i> , 2020, 80, 5189-5202.	0.4	9
35	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
36	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020, 26, 2297-2307.	3.2	28

#	ARTICLE	IF	CITATIONS
37	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Contextâ€Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. <i>Molecular Cancer Research</i> , 2020, 18, 1153-1165.	1.5	20
38	Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Anticancer Research</i> , 2020, 40, 3147-3153.	0.5	13
39	Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6â€mercaptapurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28360.	0.8	12
40	Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC). <i>Blood</i> , 2020, 136, 14-15.	0.6	25
41	Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study. <i>Blood</i> , 2020, 136, 16-17.	0.6	1
42	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. <i>Blood</i> , 2020, 136, 42-44.	0.6	8
43	Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival. <i>Blood</i> , 2020, 136, 13-14.	0.6	19
44	Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Childrenâ€™s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10519-10519.	0.8	10
45	ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 42-42.	0.6	3
46	Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A-r Infant Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2020, 136, 41-41.	0.6	0
47	Universal premedication and therapeutic drug monitoring for asparaginaseâ€based therapy prevents infusionâ€associated acute adverse events and drug substitutions. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27797.	0.8	47
48	How I treat infant leukemia. <i>Blood</i> , 2019, 133, 205-214.	0.6	82
49	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. <i>Blood</i> , 2019, 134, 741-741.	0.6	36
50	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. <i>Blood</i> , 2019, 134, 292-292.	0.6	19
51	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. <i>Blood</i> , 2019, 134, 1293-1293.	0.6	4
52	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2019, 134, LBA-1-LBA-1.	0.6	51
53	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Childrenâ€™s Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10008-10008.	0.8	31
54	B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature. <i>AJSP Review and Reports</i> , 2019, 24, 191-195.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Blinatumomab for MRD+ B-ALL: the evidence strengthens. <i>Blood</i> , 2018, 131, 1497-1498.	0.6	6
56	Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10518-10518.	0.8	1
57	Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. <i>Oncotarget</i> , 2018, 9, 35313-35326.	0.8	6
58	Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets. <i>Blood</i> , 2018, 132, 918-918.	0.6	0
59	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 612-617.	2.0	17
60	A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigatorsâ€™ Consortium study (POE 10â€™03). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26414.	0.8	57
61	FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 10931-10944.	0.8	28
62	Activity and Toxicity of Intravenous <i>Erwinia coli</i> -Derived Asparaginase Following Allergy to <i>E. coli</i> -Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 228-233.	0.8	44
63	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. <i>Clinical Cancer Research</i> , 2016, 22, 4014-4022.	3.2	56
64	Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2016, 57, 1140-1148.	0.6	46
65	Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. <i>Blood</i> , 2016, 128, 2780-2780.	0.6	62
66	Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. <i>Blood</i> , 2016, 128, 2781-2781.	0.6	5
67	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	0.6	1
68	Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted <i>in vivo</i> , and synergized with antileukemic drugs. <i>Oncotarget</i> , 2016, 7, 7268-7279.	0.8	28
69	Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL-rearranged (MLL-R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 1585-1585.	0.6	0
70	Proteomic/Transcriptomic Signatures of Infant MLL-r Rearranged B-ALL at Diagnosis and Relapse Reveal Lineage Plasticity and Diagnostic Heterogeneity. <i>Blood</i> , 2016, 128, 2697-2697.	0.6	0
71	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 414-418.	0.8	31
72	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). <i>Pediatric Blood and Cancer</i> , 2015, 62, 1717-1724.	0.8	103

#	ARTICLE	IF	CITATIONS
73	Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells. <i>Oncotarget</i> , 2015, 6, 34846-34858.	0.8	23
74	Novel agents for the treatment of childhood acute leukemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 61-79.	1.1	49
75	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	9.4	233
76	Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>Pediatric Clinics of North America</i> , 2015, 62, 61-73.	0.9	235
77	Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis. <i>Blood</i> , 2015, 126, 3651-3651.	0.6	1
78	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 3792-3792.	0.6	11
79	Identifying Subclonal Epigenetic Changes Driving Chemoresistance in Infant MLL-r Acute Lymphoblastic Leukemias. <i>Blood</i> , 2015, 126, 809-809.	0.6	4
80	rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis. <i>Oncotarget</i> , 2015, 6, 18094-18104.	0.8	76
81	POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. <i>Oncotarget</i> , 2015, 6, 30902-30918.	0.8	29
82	Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors. <i>Blood</i> , 2015, 126, 1277-1277.	0.6	0
83	A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplasm in Double Knock-in Mice with WT1 and FLT3/ITD Mutations. <i>Blood</i> , 2015, 126, 312-312.	0.6	1
84	FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2014, 74, 5206-5217.	0.4	20
85	The Biology and Targeting of FLT3 in Pediatric Leukemia. <i>Frontiers in Oncology</i> , 2014, 4, 263.	1.3	55
86	NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. <i>Experimental Hematology</i> , 2014, 42, 101-113.e5.	0.2	32
87	Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. <i>Blood</i> , 2014, 124, 3650-3650.	0.6	5
88	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2014, 124, 795-795.	0.6	19
89	Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. <i>Oncotarget</i> , 2014, 5, 8947-8958.	0.8	51
90	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 612-612.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Identifying Methylation Changes Driving Evolution of Relapse in MLL-Rearranged Acute Lymphoblastic Leukemias. <i>Blood</i> , 2014, 124, 3797-3797.	0.6	0
92	Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model. <i>Blood</i> , 2014, 124, 3572-3572.	0.6	12
93	POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 3707-3707.	0.6	0
94	Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML. <i>Molecular Cancer Research</i> , 2013, 11, 1004-1016.	1.5	89
95	Treatment of infant leukemias: challenge and promise. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 596-600.	0.9	53
96	MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. <i>British Journal of Haematology</i> , 2013, 160, 785-797.	1.2	39
97	Does hematopoietic stem cell transplantation benefit infants with acute leukemia?. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 601-604.	0.9	24
98	Preliminary Results Of a Pharmacokinetic Study Of Intravenous Asparaginase Erwinia Chrysanthemii Following Allergy To E Coli-Derived Asparaginase In Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma. <i>Blood</i> , 2013, 122, 3904-3904.	0.6	4
99	Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Blood</i> , 2013, 122, 171-171.	0.6	0
100	High Levels Of FLT3 Ligand (FL) Reverse Etoposide Resistance In FLT3-Mutant Acute Leukemia Via Substrate Inhibition: Implications For Treatment. <i>Blood</i> , 2013, 122, 1284-1284.	0.6	4
101	Extended Exposure To The CXCR4 Inhibitor Plerixafor May Lead To Enhanced Microenvironment Interactions in Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 1295-1295.	0.6	0
102	Pcft Is Silenced By DNA Methylation In Pediatric Acute Lymphoblastic Leukemia Resulting In Decreased Methotrexate Uptake. <i>Blood</i> , 2013, 122, 3768-3768.	0.6	0
103	Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis. <i>Blood</i> , 2013, 122, 1269-1269.	0.6	0
104	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 5201-5210.	0.6	123
105	A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. <i>Blood</i> , 2012, 120, 3605-3605.	0.6	1
106	TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 866-866.	0.6	1
107	Reaping the Benefits of Recent Advances for Adults With Acute Lymphoblastic Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 800-801.	2.3	1
108	The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 780-780.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Lineage, Fusion Partner and Age Differences in the Methylome of MLL-r Leukemias. <i>Blood</i> , 2012, 120, 3506-3506.	0.6	0
110	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. <i>Nature</i> , 2011, 478, 524-528.	13.7	1,656
111	The bone marrow microenvironment and leukemia: biology and therapeutic targeting. <i>Expert Review of Hematology</i> , 2011, 4, 271-283.	1.0	98
112	Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes. <i>Blood</i> , 2011, 118, 3602-3602.	0.6	1
113	MLL Rearrangement and Age At Diagnosis Are Strongly Associated with High Level Surface FLT3 Expression and Ex Vivo Sensitivity to FLT3 Inhibition: A Prospective Analysis of 54 Consecutive Infants with ALL Enrolled in Children's Oncology Group (COG) Trial AALL0631. <i>Blood</i> , 2011, 118, 568-568.	0.6	0
114	Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia. <i>Blood</i> , 2011, 118, 1410-1410.	0.6	0
115	Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects. <i>Blood</i> , 2011, 118, 2437-2437.	0.6	0
116	Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. <i>Blood</i> , 2010, 115, 4798-4809.	0.6	108
117	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. <i>Pediatric Blood and Cancer</i> , 2010, 54, 872-878.	0.8	22
118	Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model. <i>Blood</i> , 2010, 116, 145-145.	0.6	1
119	Upregulation of Surface CXCR4 In Response to Chemotherapy Confers a Stromal-Mediated Survival Advantage In Acute Leukemia. <i>Blood</i> , 2010, 116, 2734-2734.	0.6	1
120	Histone Profiling of Normal B-Precursors and Primary Pre-B Acute Lymphoblastic Leukemia Reveals Distinct Aberrant Histone Codes In MLL-Rearranged Vs. Wild Type MLL Leukemias That Correlate with Differential Expression of Key MLL Target Genes. <i>Blood</i> , 2010, 116, 2503-2503.	0.6	0
121	Statin Treatment Inhibits FLT3 Signaling by Preventing Glycosylation of the Mature Receptor and Leads to Cell Death In Mutant FLT3 Expressing Cells. <i>Blood</i> , 2010, 116, 779-779.	0.6	0
122	Novel targeted drug therapies for the treatment of childhood acute leukemia. <i>Expert Review of Hematology</i> , 2009, 2, 145-158.	1.0	28
123	Nucleophosmin (<i>NPM1</i>) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. <i>Hematological Oncology</i> , 2009, 27, 171-181.	0.8	127
124	Adding WT1 to childhood AML alphabet soup. <i>Blood</i> , 2009, 113, 5696-5697.	0.6	5
125	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study. <i>Blood</i> , 2009, 114, 3091-3091.	0.6	4
126	Glycosylation and Surface Localization Are Required for FLT3 Activation but Not for FLT3/ITD. <i>Blood</i> , 2009, 114, 2748-2748.	0.6	1



#	ARTICLE	IF	CITATIONS
127	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines.. Blood, 2009, 114, 2742-2742.	0.6	0
128	Promoter Hypermethylation in MLL-r Leukemia: Biology and Therapeutic Targeting.. Blood, 2009, 114, 3472-3472.	0.6	0
129	Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.. Blood, 2009, 114, 3776-3776.	0.6	0
130	Molecularly Targeted Therapies for Pediatric Acute Myeloid Leukemia. Paediatric Drugs, 2008, 10, 85-92.	1.3	10
131	Rapid Method for Detection of Mutations in the Nucleophosmin Gene in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2008, 10, 338-345.	1.2	19
132	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica, 2008, 93, 439-442.	1.7	74
133	High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children's Oncology Group Study. Blood, 2008, 112, 147-147.	0.6	4
134	Disruption of Leukemia Stem Cell (LSC) Interactions with Bone Marrow Stromal Niche Enhances Efficacy of FLT3 Tyrosine Kinase Inhibitors (TKI) in Vivo. Blood, 2008, 112, 383-383.	0.6	8
135	Level of FLT3 Expression in Leukemia Cells Correlates with Specific Histone Modifications and the Presence or Absence of MLL Fusion Genes, Implicating Epigenetic Regulation of FLT3 Expression. Blood, 2008, 112, 4469-4469.	0.6	2
136	Discordance of MLL-Rearranged (MLL-R) Infant ALL in Monozygotic Twins with Spontaneous Clearance of Preleukemic Clone in Unaffected Twin. Blood, 2008, 112, 2543-2543.	0.6	0
137	The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood, 2007, 110, 979-985.	0.6	193
138	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood, 2006, 108, 3477-3483.	0.6	194
139	Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Children's Oncology Group Study.. Blood, 2006, 108, 221-221.	0.6	1
140	Prolonged Exposure to FLT3 Inhibitors Leads to Resistance Via Activation of Parallel Signaling Pathways.. Blood, 2006, 108, 1380-1380.	0.6	0
141	FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood, 2005, 105, 812-820.	0.6	188
142	FLT3 Immunotherapy Can Eliminate Engraftment of ALL Cells in NOD/SCID Mice.. Blood, 2005, 106, 869-869.	0.6	0
143	FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood, 2004, 103, 267-274.	0.6	184
144	Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood, 2004, 104, 1841-1849.	0.6	82

#	ARTICLE	IF	CITATIONS
145	EB10, an Anti-FLT3 Monoclonal Antibody, Selectively Targets ALL Cell Lines and Primary ALL Blasts without Interfering with Normal Hematopoiesis.. Blood, 2004, 104, 2744-2744.	0.6	1
146	FLT3-Targeted Therapy Selectively Kills MLL-Rearranged Infant and Childhood ALL Blasts In Vitro and in Vivo.. Blood, 2004, 104, 686-686.	0.6	2
147	Single-Cell Multi-Omics Reveals Elevated Plasticity and Stem-Cell-Like Blasts Relevant to the Poor Prognosis of <i>KMT2A</i>-Rearranged Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
148	Low rate of subsequent malignant neoplasms following CAR T-cell therapy. Blood Advances, 0, , .	2.5	8